{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:23:31Z","timestamp":1794669811227,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Osteogenesis imperfecta is an inherited clinically heterogeneous disorder of bone metabolism characterized by bone and skeletal fragility and an increased risk of fractures. Pamidronate infusion was the standard treatment, but zoledronic acid is increasingly used to treat children with osteogenesis imperfecta. We conducted a systematic literature review to evaluate the efficacy and safety of intravenous zoledronic acid in the treatment of osteogenesis imperfecta in pediatric patients. A systematic review of the published literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were clinical trials and observational studies including pediatric patients (&lt;16\u2009years) with osteogenesis imperfecta treated with zoledronic acid. We selected articles published during the 20 past years. The selected languages were English and French. We included articles with a minimum sample size of five patients. Six articles fulfilled the selection criteria. The majority of patients were Chinese (58%). The predominant sex was male (65%), and the age of included patients ranged from 2.5\u2009weeks to 16.8\u2009years. For all patients, zoledronic infusions were administrated intravenously. The zoledronic treatment duration ranged from 1 to 3\u2009years. Densitometry parameters before and after zoledronic treatment were evaluated and showed significant improvement both in lumbar spine-bone mineral density <jats:italic toggle=\"yes\">Z<\/jats:italic>-score and femoral neck-bone mineral density <jats:italic toggle=\"yes\">Z<\/jats:italic>-scores. A significant decrease in fracture rate has also been noted both in vertebral and nonvertebral fracture incidence. The two most common side effects were fever and flu-like reactions. None of the patients presented severe adverse events. Zoledronic acid appeared to be well-tolerated and effective in the treatment of pediatric osteogenesis imperfecta.<\/jats:p>","DOI":"10.1097\/bpb.0000000000001104","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T22:00:27Z","timestamp":1687298427000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of intravenous Zolidronic acid in the treatment of pediatric osteogenesis imperfecta: a systematic review"],"prefix":"10.1097","volume":"33","author":[{"given":"Ines","family":"Mahmoud","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Bouden","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Sahli","sequence":"additional","affiliation":[{"name":"University of Tunis El Manar"},{"name":"Rheumatology practice, El Mourouj, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rouached","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha","family":"Ben Tekaya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawdha","family":"Tekaya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Saidane","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abdelmoula","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charles Nicolle Hospital, Tunis"},{"name":"University of Tunis El Manar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/adc.72.2.169","article-title":"Osteogenesis imperfecta, non-accidental injury, and temporary brittle bone disease.","volume":"72","author":"Smith","year":"1995","journal-title":"Arch Dis Child"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta.","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta.","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease.","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","article-title":"Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.","volume":"17","author":"Glorieux","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","article-title":"Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.","volume":"31","author":"Ward","year":"2002","journal-title":"Bone"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S8756-3282(02)00808-6","article-title":"Osteogenesis imperfecta type VII maps to the short arm of chromosome 3.","volume":"31","author":"Labuda","year":"2002","journal-title":"Bone"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ajmg.a.36784","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment.","volume":"167A","author":"Van Dijk","year":"2015","journal-title":"Am J Med Genet A"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","article-title":"Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.","volume":"34","author":"Arikoski","year":"2004","journal-title":"Bone"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s004310100844","article-title":"Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.","volume":"160","author":"Lee","year":"2001","journal-title":"Eur J Pediatr"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta.","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1515\/JPEM.2004.17.11.1511","article-title":"Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.","volume":"17","author":"Zacharin","year":"2004","journal-title":"J Pediatr Endocrinol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R15-20250526","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"R17-20250526","first-page":"485","article-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.","volume":"25","author":"Barros","year":"2012","journal-title":"J Pediatr Endocr Met"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","article-title":"Zoledronic acid treatment in children with osteogenesis imperfecta.","volume":"75","author":"Vuorimies","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study.","volume":"24","author":"Fang","year":"2018","journal-title":"Endocr Pract"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bone.2019.06.011","article-title":"Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta.","volume":"127","author":"Li","year":"2019","journal-title":"Bone"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00774-009-0149-4","article-title":"Response to zolendronic acid in children with type III osteogenesis imperfecta.","volume":"28","author":"Panigrahi","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1515\/jpem-2015-0351","article-title":"Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children.","volume":"29","author":"Kumar","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R23-20250526","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3346\/jkms.2007.22.2.209","article-title":"Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.","volume":"22","author":"Choi","year":"2007","journal-title":"J Korean Med Sci"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpeds.2004.06.066","article-title":"Short-term safety assessment in the use of intravenous zoledronic acid in children.","volume":"145","author":"Hogler","year":"2004","journal-title":"J Pediatr"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int"},{"key":"R28-20250526","first-page":"S85","article-title":"Intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfecta.","volume":"82","author":"Glorieux","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience.","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Pediatric Orthopaedics B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BPB.0000000000001104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:04:00Z","timestamp":1748297040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BPB.0000000000001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bpb.0000000000001104","relation":{},"ISSN":["1060-152X"],"issn-type":[{"value":"1060-152X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}